AGIO
Agios Pharmaceuticals, Inc.
A biopharmaceutical company in Cambridge, Massachusetts, that develops treatments for rare blood disorders by targeting cellular metabolism. Its main product, PYRUKYND (mitapivat), is an oral medicine for hemolytic anemia in adults with pyruvate kinase deficiency. Founded in 2008 by three cancer researchers, the company takes its name from the Greek word for "holy" — and sold its cancer business in 2021 to focus on rare genetic diseases.
CUSIP: 00847X104HealthcareUS1 holder
Total Value
$4.37M
Total Shares
117.7K
Net Share Change
-285.9K
Activity
1 selling
Investor
Value
Shares
Weight
Change
